The HDAC8 Knockout KYSE-30 Polyclonal Cells are a heterogeneous population of human esophageal squamous cell carcinoma cells edited via CRISPR/Cas9 to disrupt the HDAC8 gene. This polyclonal knockout pool retains the inherent diversity of the parental line, making it suitable for assays where population-level phenotypes better reflect tumor heterogeneity and reducing clonal artifact.
The KYSE-30 cell line originates from a poorly differentiated esophageal squamous cell carcinoma of a 64-year-old male patient. An established model for esophageal carcinoma, KYSE-30 exhibits aggressive growth and is widely used to study the molecular pathology of this cancer. Its well-characterized genomic background supports functional genomics and drug response investigations.
HDAC8 is a histone deacetylase that removes acetyl groups from lysine residues on histones H3 and H4, as well as non-histone substrates including the cohesin subunit SMC3, the tumor suppressor p53, and estrogen receptor alpha. Histone deacetylation promotes chromatin condensation and transcriptional silencing, while SMC3 deacetylation regulates cohesin loading and genome organization. HDAC8 activity is modulated by PKA-mediated phosphorylation and stress signaling via CREB. It interacts with MEF2 transcription factors and the N-CoR/SMRT co-repressor complex, integrating inputs from the p53, JAK-STAT, and Notch pathways to influence cell cycle progression and apoptosis.
In esophageal squamous cell carcinoma, HDAC8 overexpression is linked to enhanced proliferation and survival, in part by deacetylating and inactivating p53 and by altering cohesin function. Disrupting HDAC8 in KYSE-30 cells allows dissection of these oncogenic mechanisms. The model can be used to examine changes in histone acetylation, p53 target gene expression, SMC3 chromatin occupancy, and effects on cell cycle arrest and apoptosis, enabling isolation of HDAC8-specific contributions to tumor cell phenotypes.
This HDAC8 knockout polyclonal pool supports diverse assays including western blot for HDAC8 and acetylated histones, ChIP-qPCR for histone acetylation mapping, RNA-seq for transcriptomic analysis, and flow cytometry for cell cycle and apoptosis. Drug sensitivity testing with HDAC8 inhibitors can reveal therapeutic vulnerabilities, while migration and invasion assays probe metastatic potential. For detailed product information and lot-specific data, please contact Ascent Research.
